The Hematti Laboratory
Faculty > Peiman Hematti
Peiman Hematti
Assistant Professor, Medicine, Hematology/Oncology Section
pxh@medicine.wisc.edu
Organ System/Disease Focus
Hematopoietic (blood) system; Treatment of hematological malignancies through hematopoietic stem cell transplantation
Aligned Research Focus
Bone marrow (hematopoietic and mesenchymal) stem cell biology
Research Description
Peiman Hematti, MD joined the Section of Hematology/Oncology/Bone Marrow Transplantation at the University of Wisconsin-Madison as an Assistant Professor in the Department of Medicine in July 2004. Dr. Hematti completed a combined Internal Medicine/Pediatrics residency at the Cleveland Clinic Foundation and then Clinical Hematology fellowship at the National Heart, Lung, and Blood Institute of the National Institutes of Health. While at NIH he spent 4 years in the laboratory of Dr. Cynthia Dunbar studying the cellular biology hematopoietic stem cells. Dr. Hematti's participates in clinical care of bone marrow transplant patients. He is also director of Clinical Hematopoietic Cell Processing Laboratory, and medical director of Hematopoietic Cell Collection facility at University of Wisconsin Hospital and Clinics. In that capacity he oversees all peripheral blood and bone marrow collections for hematopoietic cell transplantation or other cellular therapy applications. His clinical research interest is in the use of mesenchymal stem cells for treatment of graft versus host disease and other immune dysregulation disorders, novel cell therapies for hematological malignancies, and use of bone marrow stem cells in regenerative medicine.
Dr. Hematti's laboratory research focuses on investigating the immune modulatory properties of mesenchymal stem cells. He is collaborating with many investigators on the UW-campus studying the potential of these cells in many different pre-clinical models. He is also actively pursuing the goal of generating clinical- applicable mesenchymal stem cells at UW-Waisman GMP facility. Generation of clinically-grade FDA-approved mesenchymal stem cells will enable all investigators on the campus to test these cells in their clinical trials of choice.
Selected References
Hematti P, Sloand EM, Carvallo CA, Albert MR, Yee CL, Fuehrer MM, Blancato JK, Kearns WG, Barrett JA, Childs RW, Vogel JC, Dunbar CE. Absence of donor-derived keratinocyte stem cells in skin tissues cultured from patients after mobilized peripheral blood hematopoietic stem cell transplantation. Exp Hematol (8):943-9, 2002.
Hematti P, Sellers SE, Agricola BA, Metzger ME, Donahue RE, Dunbar CE. Retroviral transduction efficiency of G-CSF+SCF mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L mobilized cells in nonhuman primates. Blood 101:2199-2205., 2003.
Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, Sellers S, Holt IE, Eckfeldt CE, Sharma Y, Schmidt M, von Kalle C, Persons DA, Billings EM, Verfaillie CM, Nienhuis AW, Wolfsberg TG, Dunbar CE, Calmels B. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2(12):e423, 2004.
Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE, Hematti P. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in non-human primates. Blood 107(9): 3772-3778, 2006.
Trivedi P, Hematti P., Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells, Exp Hematol. 2008 Mar;36(3):350-9.